Extracellular association of APP and tau fibrils induces intracellular aggregate formation of tau by unknown
1 3
Acta Neuropathol (2015) 129:895–907
DOI 10.1007/s00401-015-1415-2
ORIGINAL PAPER
Extracellular association of APP and tau fibrils induces 
intracellular aggregate formation of tau
Muneaki Takahashi1,2 · Haruka Miyata1 · Fuyuki Kametani1 · Takashi Nonaka1 · 
Haruhiko Akiyama1 · Shin‑ichi Hisanaga2 · Masato Hasegawa1 
Received: 14 January 2015 / Revised: 19 March 2015 / Accepted: 20 March 2015 / Published online: 14 April 2015 
© The Author(s) 2015. This article is published with open access at Springerlink.com
spreading of tau pathologies in AD by serving as a 
receptor of abnormal tau aggregates.
Keywords Tau · Amyloid precursor protein · 
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder, characterized by the deposition of two 
kinds of filamentous aggregates: extracellular senile 
plaque consisting of amyloid β (Aβ) and intracellular 
paired helical filaments consisting of tau proteins. Aβ 
is produced by β-secretase- and γ-secretase-mediated 
cleavage of amyloid precursor protein (APP). The APP 
gene is located on chromosome 21, and trisomy of this 
chromosome is associated with Down’s syndrome, which 
exhibits an AD-like pathology. Furthermore, several mis-
sense mutations of the APP gene at or near the cleavage 
sites cause Aβ production in familial forms of AD [4, 11, 
40, 41]. Consequently, abnormal production and deposi-
tion of neurotoxic Aβ were proposed to be the primary 
cause of AD: the amyloid cascade hypothesis [53]. Tau 
protein is one of the microtubule-associated proteins 
that stabilize microtubules and promote their assembly 
[23]. Six tau isoforms are expressed by alternative splic-
ing of the mRNA in adult human brain, but in AD, all 
these tau isoforms are accumulated in hyperphosphoryl-
ated and partially ubiquitinated forms as a unique paired 
helical filament (PHF) structure in neurofibrillary tangles 
and threads. Both Aβ and tau fibrils in AD brains have 
a cross-β structure similar to that of abnormal prion 
protein in Creutzfeldt–Jakob disease [20]. The distribu-
tion and spreading of abnormal tau pathology in AD are 
Abstract Alzheimer’s disease (AD) is characterized by 
extracellular amyloid β (Aβ) deposition and intracellular 
tau aggregation. Many studies have indicated some asso-
ciation between these processes, but it remains unknown 
how the two pathologies are linked. In this study, we 
investigated whether expression of amyloid precursor 
protein (APP) influences extracellular seed-dependent 
intracellular tau accumulation in cultured cells. Treat-
ment of tau-expressing SH-SY5Y cells with Aβ fibrils 
did not induce intracellular tau aggregation. On the 
other hand, in cells expressing both tau and APP, treat-
ment with tau fibrils or Sarkosyl-insoluble tau from AD 
brains induced intracellular tau aggregation. The seed-
dependent intracellular tau aggregation was not induced 
by expression of APP lacking the extracellular domain. 
The amount of phosphorylated tau aggregates in cul-
tured cells was dose dependently elevated in response 
to increased levels of APP on the cell membrane. Our 
results indicate that the extracellular region of APP is 
involved in uptake of tau fibrils into cells, raising the 
possibility that APP, but not Aβ, influences cell-to-cell 
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temporally and topologically stereotypical, and correlate 
with clinical phenotype [1].
Based on the amyloid cascade hypothesis, considerable 
effort has been invested in understanding the relationship 
between Aβ and tau. Many studies have found some asso-
ciation between these proteins; for example, cytotoxic Aβ 
induces phosphorylation of tau [3, 7, 22, 33]. However, it 
remains unclear how they are associated. Vaccination with 
Aβ results in clearance of amyloid plaques in patients 
with AD, but fails to improve clinical symptoms or tau 
pathologies [10, 29, 34], suggesting that inhibition of Aβ 
formation or increased clearance of Aβ may not influence 
tau pathologies. In addition, Braak et al. [2] reported that 
tau aggregation precedes diffuse plaque deposition, and 
they hypothesized that Aβ may be released from non-
junctional varicosities of axons generated from abnormal 
tau-containing brainstem nuclei in sporadic AD.
Recent studies using cellular and animal models have sug-
gested that intracellular abnormal protein pathologies, includ-
ing tauopathy, spread by a prion-like mechanism [9, 42]. 
Namely, an abnormal form of these proteins once formed in 
cells promotes the conversion of monomeric normal protein 
to an abnormal form. The abnormal proteins are also trans-
mitted from cell to cell, resulting in spreading of the patholo-
gies. Prion-like propagation of abnormal tau and α-synuclein 
has been demonstrated in transgenic and non-transgenic wild-
type mouse models by direct inoculation into mouse brains of 
fibrils made of recombinant proteins and abnormal proteins 
from brains of patients [5, 6, 19, 31, 32, 35, 39].
Propagation of these proteins has been proposed to occur 
through various mechanisms, including indirect transmis-
sion by exocytosis and endocytosis, and direct transmission 
via nanotubes [8, 12, 27, 37]. However, nothing is known 
about the molecular mechanisms by which these intracellu-
lar abnormal proteins are secreted from cells and incorpo-
rated into other cells, and whether or not incorporation of 
these extracellular proteins is receptor mediated.
In this study, we investigated whether Aβ or its precursor 
protein APP is involved in incorporation and propagation 
of intracellular abnormal proteins. We show that overex-
pression of APP accelerated extracellular seed-dependent 
aggregation of tau, and also that APP-expressing cells 
treated with tau fibrils exhibited induction of Sarkosyl-
insoluble tau aggregates in the absence of any transfection 
reagent. In contrast, overexpression of APP lacking the 
extracellular domain or treatment with Aβ did not acceler-
ate tau aggregation. These results suggest that the extracel-
lular domain of APP is involved in the incorporation of tau 
fibrils into cells; in other words, APP may serve as a recep-
tor of abnormal tau protein seeds.
Materials and methods
Antibodies
Anti-tau antibodies used in this study were as follows: T46 
(epitope: 395–432; Invitrogen), pS396 (epitope: p-Ser-396; 
Calbiochem), HT7 (epitope: 159–63; Thermo Scientific), 
AT8 (epitope: p-Ser-202 and p-Thr-205; Thermo Scien-
tific). Anti-APP antibodies used in this study were as fol-
lows: 22C11 (epitope: 66–81; Millipore), R37 (epitope: 
756–770, as described [24, 28]).
Expression and purification of tau protein
An expression plasmid, pRK172, containing human 4R1N 
tau was expressed in E. coli BL21 (DE3). Recombinant 
4R1N tau protein was purified as described [17], and dia-
lyzed against 30 mM Tris–HCl, pH 7.5. The dialyzed sam-
ple was centrifuged at 113,000×g for 20 min at 4 °C and 
the supernatant was used as recombinant tau monomer. 
Protein concentration of tau was determined as described 
[57].
Preparation of recombinant tau fibrils
Purified recombinant tau (1 mg/mL) and heparin (Acros 
Organics, 0.1 mg/mL) were incubated at 37 °C in 30 mM 
Tris–HCl, pH 7.5 containing 10 mM DTT and 0.1 % 
sodium azide [44]. After incubation for over 1 week, the 
mixtures were ultracentrifuged at 113,000×g for 20 min. 
The pellet was resuspended in PBS, sonicated using a Titec 
sonicator, and used as tau fibrils. The protein concentration 
of the sample was determined.
Preparation of Sarkosyl‑insoluble fraction
Brain samples of 0.5 g from patients with AD (age 80, 
Braak stage V–VI, occipital lobe) were homogenized in 
10 mL of homogenization buffer (HB: 10 mM Tris–HCl, 
pH 7.5 containing 10 % sucrose, 0.8 M NaCl, 1 mM 
EGTA). Sarkosyl was added to the homogenates (final 
concentration: 2 %), which were then incubated for 
30 min at 37 °C and centrifuged at 20,000×g for 10 min 
at 25 °C. The supernatant was centrifuged at 100,000×g 
for 20 min at 25 °C. The pellets were further washed with 
sterile saline and centrifuged at 100,000×g for 20 min. 
The resulting pellets were used as Sarkosyl-insoluble 
fraction (ppt). This study was approved by the research 
ethics committee of Tokyo Metropolitan Institute of Med-
ical Science.
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Cell culture, transfection of expression plasmids 
into cells, and treatment of cells with tau fibrils
Human neuroblastoma SH-SY5Y cells were routinely cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)/
F12 medium (Sigma-Aldrich) supplemented with 10 % 
(v/v) fetal calf serum, penicillin–streptomycin–glutamine 
(Gibco), and MEM nonessential amino acids solution 
(Gibco) in a humidified atmosphere containing 5 % CO2 at 
37 °C. In this study, SH-SY5Y cells were not neuronally 
differentiated. For transient expression, the cells were 
grown to 30–50 % confluence in collagen-coated six-well 
culture dishes, and transfected with plasmids (1 μg) using 
FuGENE6 (Roche) according to the manufacturer’s instruc-
tions. As tau plasmids, we used human 3R1N, 4R1N, and 
HA-4R1N tau cDNA in pcDNA3.1 vector. As APP plas-
mids, we employed human APP-695 (wild-type (WT), 
F690P, KM670/671NL, V717F, V717G) and APP-C99 
cDNA in pEFBOS [38]. APP mutations are indicated as the 
location of mutation in APP770. Under our conditions, the 
efficiency of transfection was about 20 %. In treatment of 
cells with tau fibrils, the culture medium was exchanged at 
24 h after transfection of expression vector, and tau fibrils 
(2 μg) were added. Cells were incubated for 24 h. Then, 
the medium was exchanged again, and cells were incubated 
for a further 1–2 days.
Gel electrophoresis and immunoblotting
The cells were washed with PBS, harvested by centrifuga-
tion (1800×g, 5 min), and extracted with 150 μL of lysis 
buffer [50 mM Tris–HCl, pH 7.5, 0.15 M NaCl, 5 mM 
EDTA, 5 mM EGTA, mixture of protease inhibitors]. 
The extract was briefly sonicated and ultracentrifuged at 
113,000×g for 20 min at 4 °C, then the supernatant was 
collected as a Tris-soluble fraction (TS). The protein con-
centration was determined by BCA assay. The pellet was 
solubilized by sonication in 100 μL of lysis buffer con-
taining 1 % Triton X-100 and ultracentrifuged, and the 
supernatant was collected as a Triton X-100-soluble frac-
tion (TX). The pellet was solubilized in 100 μL of lysis 
buffer containing 1 % Sarkosyl, then ultracentrifuged, and 
the supernatant was collected as Sarkosyl-soluble fraction 
(Sar). The pellet was solubilized in 100 μL of SDS-sample 
buffer and collected as detergent-insoluble pellet (ppt).
Each sample was separated by 10 % SDS-PAGE, and 
transferred onto polyvinylidene difluoride membrane (Mil-
lipore). The membranes were blocked with 3 % gelatin and 
incubated overnight with the indicated primary antibody in 
10 % calf serum at room temperature. Next, the membranes 
were washed with PBS and then incubated with a biotin-
labeled secondary antibody (Vector) for 1–2 h at room 
temperature. Signals were detected using an ABC staining 
kit (Vector). All experiments were performed at least three 
times, and representative results are shown.
Confocal immunofluorescence microscopy
SH-SY5Y cells on coverslips were cultured as described 
above. Then, the cells on the coverslips were fixed with 
4 % paraformaldehyde, and permeabilized with 0.2 % 
Triton X-100 in PBS for 10 min. After blocking for over 
30 min in 5 % BSA in PBS, samples were incubated with 
primary antibody diluted with 5 % BSA in PBS for 1 h at 
37 °C. After washing, samples were incubated with Alexa 
Fluor 488- or 568-labeled goat anti-rabbit or mouse IgG for 
1 h at 37 °C. After washing, the samples were further incu-
bated with TO-PRO-3 (Invitrogen) diluted with PBS for 1 h 
at 37 °C. The cells were analyzed using an LSM780 confo-
cal laser microscope (Carl Zeiss).
Immunoelectron microscopy
For immunoelectron microscopy, cells overexpressing both 
HA-4R1N and APP were treated with 4R1N tau fibrils as 
described above. After incubation, they were harvested and 
suspended in 1 mL of homogenization buffer containing 
1 % Sarkosyl. After incubation for 30 min at room tem-
perature, the homogenates were centrifuged at 113,000×g 
for 20 min at 25 °C. The resulting pellets were suspended 
in 30 mM Tris–HCl, pH 7.5, and then placed on collodion-
coated 300-mesh nickel grids. After drying, the grids were 
blocked with 30 mM Tris–HCl, pH 7.5 containing 2 mg/
mL BSA, and incubated overnight with anti-HA or AT8 
antibody at a dilution of 1:200. The grids were rinsed and 
reacted with secondary antibody conjugated to 10-nm gold 
particles (1:50), then rinsed again and stained with 2 % 
(v/v) phosphotungstate. Micrographs were obtained with a 
JEOL JEM-1400 electron microscope.
Results
Tau fibrils bind on cells expressing APP
To explore the putative link between Aβ deposition and tau 
aggregation, we first examined whether there is any asso-
ciation between APP and tau. We prepared synthetic tau 
fibrils by incubation of purified tau with heparin, and con-
firmed fibril formation by means of electron microscopy 
(Fig. 1a). Next, SH-SY5Y cells were treated with mono-
meric soluble form of recombinant tau or insoluble tau 
fibrils for 1 day, then immunostained with anti-tau (T46) 
and anti-APP (R37) antibodies, and analyzed by confo-
cal laser microscopy. These cells are not transfected with 
tau, and total treated recombinant tau is detected by T46. 
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Soluble tau was not detected, either in untransfected cells 
(Fig. 1b) or in cells expressing APP after treatment with 
monomeric tau (Fig. 1c). In contrast, diffuse T46-positive 
tau staining was detected on the control cells treated with 
tau fibrils (Fig. 1d). Furthermore, strong tau staining was 
observed on APP-expressing cells by incubation with tau 
fibrils, and this staining was colocalized with APP staining 
(Fig. 1e). Three representative cross-sectional images of 
the cells in three dimensions showed that tau fibrils exist 
both inside and outside of the cells (Fig. S1). These results 
indicate that fibrillar tau interacts with APP, but soluble tau 
does not. However, immunoprecipitation experiments using 
tau or APP antibodies failed to detect the association of tau 
fibrils with APP, suggesting that the interaction may not be 
strong (data not shown).
Exogenously added recombinant tau fibrils induce 
intracellular aggregation in cells expressing tau 
and APP
It has been reported that tau fibrils are incorporated into 
cells in the presence of transfection reagent and induce 
seed-dependent aggregation in tau-expressing cells [42]. In 
this study, we investigated seed-dependent tau aggregation 
Fig. 1  Effect of treatment with 
monomeric tau or tau fibrils 
on cells. Electron micros-
copy of tau fibrils used for 
the treatment of cells (a). The 
scale bar represents 200 nm. 
Immunohistochemical analysis 
of cells treated with 4R1N tau 
monomers (b), APP-expressing 
cells treated with 4R1N tau 
monomers (c), cells treated with 
4R1N tau fibrils (d), and APP-
expressing cells treated with 
4R1N tau fibrils (e). Cells were 
immunostained with R37 (APP, 
green) and T46 (tau, Red), and 
counterstained with TO-PRO-3 
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in the absence of transfection reagent. We examined 
whether expression of APP affects tau aggregate formation 
in cultured cells. Cells expressing APP were treated with 
tau fibrils for 24 h and immunostained with anti-APP anti-
body R37 and anti-phosphorylated tau antibody AT8, and 
the cells were analyzed by confocal laser microscopy. AT8 
antibody specifically detects phosphorylated tau. Since 
phosphorylation occurs inside the cells, intracellular tau 
fibrils can be distinguished from extracellular tau fibrils. In 
a few APP-expressing cells treated with tau fibrils, small 
AT8-positive dot-like structures were detected in the cell 
cytoplasm (Fig. 2a, b). Cross-sectional images of APP-
expressing cells with AT8-positive tau in three dimensions 
showed that the signal of AT8-positive tau is located intra-
cellularly (Fig. 2b). Namely, tau fibrils are incorporated 
into the cells and then hyperphosphorylated.
Furthermore, when cells expressing both tau and APP 
were treated with tau fibrils for 24 h, and then for another 
24 h after medium change, larger phosphorylated tau inclu-
sions were observed and the frequency of the inclusions 
in cells was also increased. Two representative results are 
shown (Fig. 2c, d). Interestingly, these cells showed focal 
APP immunostaining that was partially colocalized with 
AT8-positive staining (Fig. 2c). These results indicate that 
treatment of APP-expressing cells with tau fibrils induces 
conversion of plasmid-derived soluble tau into hyperphos-
phorylated and aggregated tau independently of any trans-
fection reagent.
Biochemical analysis of seed‑dependent aggregation 
of tau
To confirm the immunocytochemical observations, we 
performed biochemical analysis. SH-SY5Y cells were 
transiently transfected overnight with plasmids for expres-
sion of 4R1N tau and/or APP, and then the cells were 
treated with or without tau fibrils (1 μg/mL) for 24 h. After 
medium exchange, the cells were cultured for another 48 h, 
harvested and differentially extracted with Tris–Saline (TS), 
1 % Triton X-100 (TX), 1 % Sarkosyl (Sar), leaving the 
Fig. 2  Immunohistochemi-
cal analysis of the effect of 
APP on seed-dependent tau 
aggregation in cultured cells. 
Immunohistochemical analysis 
of APP-expressing cells treated 
with 4R1N tau fibrils (a). Cross-
sections of APP-expressing 
cells after incorporation of tau 
fibrils (b). 1 Optical section 
(X–Y) at the depth indicated 
by the blue lines in (2) and (3). 
2 Cross-sectional Y–Z image 
along the green line shown 
in (1). 3 Cross-sectional X–Z 
image along the red line shown 
in (1). Immunohistochemical 
analysis of cells expressing both 
4R1N tau and APP, and treated 
with tau fibrils (c, d). Cells were 
immunostained with R37 (APP, 
green) and AT8 (hyperphospho-
rylated tau, red), and counter-
stained with TO-PRO-3 (Blue). 










900 Acta Neuropathol (2015) 129:895–907
1 3
pellet fraction (ppt). The fractions were subjected to immu-
noblot analysis using several anti-tau and anti-APP antibod-
ies. As shown in Fig. 3a, a single faint tau band at 50 kDa 
was endogenous tau, which was detected in TS fraction with 
HT7 and T46 in cells transfected with only APP. In cells 
transfected with 4R1N tau or both APP and tau, a broad 
tau band was detected at 60 kDa in the TS and TX fractions 
with HT7, T46 and pS396. However, no immunoreactivity 
was detected in the Sar-soluble and insoluble fractions (ppt) 
in these cells, indicating that simple expression of tau and 
APP cannot elicit intracellular tau aggregation. Similarly, no 
insoluble tau bands were detected in untransfected cells or 
in cells transfected with tau, even if the cells were treated 
with tau fibrils, indicating that extracellular tau fibrils are 
hardly introduced into cells under these conditions [42]. 
In contrast, when cells were transfected with both tau and 
APP, and treated with exogenous tau fibrils, pS396- or 
AT8-positive hyperphosphorylated tau was detected in the 
Sar-soluble and insoluble fractions of the cells; thus, APP 
expression is essential for Sar-insoluble intracellular tau 
aggregation without transfection reagent. Also, tau has to be 
overexpressed in the recipient cells, because the amount of 
endogenous tau is too small to induce aggregation.
Similar results were obtained in cells expressing a 3R tau 
isoform. An increased amount of Sar-soluble and insoluble 
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Fig. 3  Immunoblot analysis of the effect of APP on seed-dependent 
tau aggregation in cultured cells. Immunoblot analysis of lysates from 
cells transfected with APP, cells transfected with 4R1N tau, cells 
transfected with both 4R1N tau and APP, cells transfected with APP 
and treated with 4R1N tau fibrils, cells transfected with 4R1N tau and 
treated with 4R1N tau fibrils, and cells transfected with both 4R1N 
tau and APP and treated with 4R1N tau fibrils (a). Immunoblot analy-
sis of lysates from cells transfected with only APP, and cells trans-
fected with both APP and 3R1N tau and treated with 3R1N tau fibrils 
(b). Immunoblot analysis of lysates from cells transfected with both 
APP and 4R1N tau and treated with 4R1N tau monomers or 4R1N 
tau fibrils (c). Cells were extracted successively to obtain Tris–HCl-
soluble fraction (TS), Triton X-100 soluble fraction (TX), and Sarko-
syl-soluble fraction (Sar), leaving the pellet fraction (ppt). Tau was 
detected with HT7 (159–163), T46 (395–432), pS396 (p-Ser-396), 
and AT8 (p-Ser-202 and p-Thr-205). APP was detected with 22C11
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when the cells were treated with 3R1N tau fibrils (Fig. 3b). 
The aggregating ability of 4R tau was essentially the same 
as that of 3R tau (not shown). Thus, the results clearly show 
that expression of APP accelerates seed-dependent intracel-
lular tau aggregation in the cells, suggesting that incorpora-
tion of extracellular tau fibrils into cells is dependent on the 
expression of APP.
To confirm that tau fibrils, not monomers, induce seed-
dependent intracellular tau aggregation, SH-SY5Y cells 
expressing both tau and APP were treated with 4R1N tau 
monomer (10 μg/mL) or fibrils (1 μg/mL) and analyzed 
by immunoblotting. As shown in Fig. 3c, Sar-soluble and 
insoluble tau was detected in cells treated with tau fibrils, 
but no such tau was detected in cells treated with mono-
meric tau, indicating that only fibrillar tau can induce seed-
dependent tau aggregation.
To distinguish plasmid-derived intracellular tau from 
tau fibrils introduced as seeds, we used a plasmid encoding 
hemagglutinin (HA)-tagged 4R1N tau. SH-SY5Y cells were 
transiently transfected with both HA-tagged tau and APP, 
and then transduced with tau fibrils. This treatment also 
induced accumulation of pS396-positive hyperphosphoryl-
ated tau in the Sar-soluble and insoluble fractions, which 
were labeled with anti-HA antibody (Fig. 4a), indicating that 
the insoluble tau consists of plasmid-derived exogenous tau. 
The Sar-insoluble fraction was further analyzed by immuno-
electron microscopy, which confirmed accumulation of anti-
HA-positive (Fig. 4b right panel) and AT8-positive (Fig. 4b 
right panel) filamentous tau of 10–15 nm width.
Tau aggregates from AD brains also accelerate 
intracellular tau aggregation in APP‑expressing cells
To examine whether Sar-insoluble fraction prepared from 
AD brains accelerates the formation of intracellular tau 
aggregates, SH-SY5Y cells were transfected with both APP 
TS  TX  Sar ppt
(kDa) 


















4R1N Tau fibrils 
Fig. 4  Immunoblotting and immunoelectron microscopic analyses of 
tau in cells expressing both APP and HA-tagged 4R1N tau. Immuno-
blot analysis of lysates from cells transfected with both HA-4R1N tau 
and APP, cells transfected with HA-4R1N tau and treated with 4R1N 
tau fibrils, and cells transfected with both HA-4R1N tau and APP and 
treated with 4R1N tau fibrils (a). Cells were sequentially extracted to 
obtain Tris-soluble (TS), Triton X-100-soluble (TX), and Sarkosyl-
soluble (Sar) fractions, leaving the pellet fraction (ppt). HA-4R1N tau 
was detected with pS396 (p-Ser-396) and anti-HA antibodies. Immu-
noelectron microscopy of tau in the Sar-insoluble fraction from cells 
transfected with both HA-4R1N tau and APP and treated with 4R1N 
tau fibrils (b). Anti-HA-positive (left panel) and AT8 (p-Ser-202 and 
p-Thr-205)-positive (right panel) filaments were observed. Scale bars 
represent 100 nm
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and 4R1N tau, followed by incubation with Sar-insoluble 
fraction prepared from AD brains. Confocal laser micros-
copy of the cells revealed small AT8-positive dot-like 
structures or diffusely stained hyperphosphorylated tau in 
cells expressing APP, which are positive for R37 staining. 
Two representative results are shown (Fig. 5a). Some of 
the AT8-positive structures are colocalized with R37, sug-
gesting that tau fibrils, mostly in the form of PHFs, in the 
Sarkosyl-insoluble fraction of AD brains are incorporated 
into cells expressing APP.
To confirm this idea biochemically, cells treated with 
the Sar-insoluble fraction of AD brain were harvested and 
subjected to immunoblot analysis. As shown in Fig. 5b, 
Sar-soluble and insoluble tau bands were detected with 
anti-pS396 and HT7 antibodies, which are associated with 
expression of APP, although the intensities of these bands 
were slightly weaker than those of cells treated with recom-
binant tau fibrils. These results suggest that pathological 
tau in brains of AD patients also works as seeds for intra-
cellular tau aggregation in cells overexpressing APP even 
in the absence of any transfection reagent.
Extracellular domain of APP is required to induce 
extracellular fibril‑dependent intracellular tau 
aggregation
Given that expression of APP accelerates seed-dependent 
intracellular tau aggregation, it appears likely that APP play 
an important role in uptake of extracellular tau fibrils and 
in aggregate formation of tau in cells. Therefore, we inves-
tigated which domain of APP is required for the intracel-
lular tau aggregation. SH-SY5Y cells transfected with both 
4R1N tau and wild-type (WT) APP or a truncated form of 
APP (C99), which lacks the N-terminal extracellular region 
of APP, were incubated with tau fibrils (1 μg/mL) for 24 h, 
and cultured for another 48 h after medium exchange. Then, 
the cells were harvested, fractionated and subjected to 
immunoblot analysis (Fig. 6a). Quantitative analysis of the 
immunoblot is in sharp contrast to the strong tau immuno-
reactivities in the Sar-soluble (Fig. 6b) and insoluble frac-
tions (Fig. 6c) of cells transfected with WT-APP: tau bands 
were barely detectable in those fractions of cells expressing 
APP-C99. This result clearly indicates that the extracellular 
domain of APP is required for seed-dependent intracellular 
tau aggregation. Expression of WT-APP or of the truncated 
form C99 was confirmed by immunoblot analysis with R37 
antibody (Fig. 6d). WT-APP and APP-C99 were detected at 
about 100 kDa and 15 kDa, respectively.
Next, we investigated whether the seed-dependent tau 
aggregation is correlated with the protein levels of APP. 
The F690P mutation of APP is known to affect the cleav-
age of APP by α-secretase and to increase the protein lev-
els of APP [16]. Cells expressing both tau and WT-APP 
or the F690P mutant APP were treated with tau fibrils 
(1 μg/mL) for 1 h, and cultured for 72 h after medium 
change. Then, the cells were harvested, fractionated and 
Fig. 5  Effect of APP on AD 
Sarkosyl ppt-dependent 4R1N 
tau aggregation in cultured 
cells. Immunohistochemical 
analysis of cells expressing both 
4R1N tau and APP, and treated 
with AD Sarkosyl ppt (a). Cells 
were immunostained with R37 
(APP, Green) and AT8 (hyper-
phosphorylated tau, Red), and 
counterstained with TO-PRO-3 
(Blue). Scale bars represent 
20 μm. Immunoblot analysis of 
lysates from cells transfected 
with both 4R1N tau and APP, 
cells transfected with 4R1N tau 
and treated with AD Sarkosyl 
ppt, and cells transfected both 
4R1N tau and APP and treated 
with AD Sarkosyl ppt (b). Cells 
were extracted successively to 
obtain Tris–HCl-soluble frac-
tion (TS), Triton X-100 soluble 
fraction (TX), and Sarkosyl-sol-
uble fraction (Sar), leaving the 
pellet fraction (ppt). Detection 
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subjected to immunoblot analysis (Fig. 6e). The Sar-sol-
uble (Fig. 6f) and insoluble (Fig. 6g) tau bands of cells 
expressing F690P mutant APP were quantitatively more 
intense than those of cells expressing WT-APP. Expres-
sion levels of APP F690P were increased by about 36 % 
compared with WT-APP (Fig. 6h). This result suggests 
that elevated expression of APP at the cell membrane may 
promote the formation of intracellular tau aggregates in 
these cells.
Effects of APP pathogenic mutations and Aβ42 
on intracellular tau aggregation
In familial forms of AD, several pathogenic mutations 
in the APP gene have been identified, and most of these 
mutants are reported to increase Aβ production or the ratio 
of Aβ42/40 [4, 11, 40, 41]. Therefore, we investigated 
whether these APP mutations influence seed-dependent tau 
aggregation in cultured cells. SH-SY5Y cells expressing 
WT-APP or a mutant (KM670/671NL, V717F, V717G or 
V717I) together with 4R1N tau were treated with tau fibrils 
(1 μg/mL) for 24 h, then cultured for another 48 h after 
medium change and analyzed by immunoblot analysis. As 
shown in Fig. 7a, c, expression levels of tau or APP were 
similar among the samples, and the levels of Sar-soluble 
and insoluble tau were comparable (Fig. 7b). No significant 
difference was detected even after normalizing the data for 
the amount of APP (data not shown), suggesting that these 
mutations may not affect incorporation of tau fibrils or 
intracellular tau aggregation. We also analyzed the effect of 
extracellular Aβ monomer on intracellular tau aggregation. 
SH-SY5Y cells expressing 4R1N tau were treated with 
both Aβ42 monomer (0–2 μM) and tau fibrils (1 μg/mL) 
for 24 h, cultured for another 48 h, and then subjected to 
immunoblot analysis (Fig. 7d). As a positive control, cells 
were transfected with expressing 4R1N tau and APP, and 
Fig. 6  Effect of the extracellu-
lar domain of APP on intracel-
lular tau aggregation. Immu-
noblot analysis of lysates from 
cells transfected with 4R1N 
tau, cells transfected with both 
4R1N tau and APP, and cells 
transfected with both 4R1N 
tau and APP-C99. All cells 
were treated with 4R1N tau 
fibrils (a). In the lower panel, 
the Sarkosyl-soluble fraction 
and Sarkosyl-insoluble fraction 
detected by pS396 are shown. 
The results are expressed as 
means +SE (n = 3). WT-APP 
was taken as 100 %. **p < 0.01; 
***p < 0.001 by Student’s t test 
against the value of none (b, c). 
These cells were also detected 
using R37 (d). Immunoblot 
analysis of lysates from cells 
transfected with 4R1N tau, cells 
transfected with both 4R1N tau 
and APP, and cells transfected 
with both 4R1N tau and APP-
F690P. All cells were treated 
with 4R1N tau fibrils (e). In 
the lower panel, the Sarkosyl-
soluble fraction and Sarkosyl-
insoluble fraction detected by 
pS396 are shown. The results 
are expressed as means +SE 
(n = 4). WT-APP was taken as 
100 %. **p < 0.01 by Stu-
dent’s t test against the value of 
none (f, g). The Triton X-100 
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treated with tau fibrils. As shown in Fig. 7e, we confirmed 
accumulation of phosphorylated tau in insoluble fractions 
of the cells transfected with APP; however, no tau bands 
were detected in cells treated with Aβ42, clearly indicating 
that extracellular Aβ42 does not promote intracellular tau 
aggregation.
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Fig. 7  The effect of APP pathogenic mutant and amyloid β on 
intracellular tau aggregation. Immunoblot analysis of lysates from 
cells transfected with 4R1N tau, cells transfected with both 4R1N 
tau and WT-APP, cells transfected with both 4R1N tau and APP 
KM670/671NL, cells transfected with both 4R1N tau and APP 
V717F, cells transfected with both 4R1N tau and APP V717G, and 
cells transfected with both 4R1N tau and APP V717I. All cells were 
treated with 4R1N tau fibrils (a). The Triton X-100 soluble fraction 
detected by 22C11 (b) and the Sarkosyl-insoluble pellet fraction 
detected by pS396 (c) are shown. The results are expressed as means 
+SE (n = 3). WT-APP was taken as 100 %. Immunoblot analysis of 
lysates from cells transfected with 4R1N tau and treated with amy-
loid β (0–2 μM), and cells transfected with both 4R1N tau and APP. 
All cells were treated with 4R1N tau fibrils (d). The Sarkosyl-insolu-
ble pellet fraction is shown (e). Cells were extracted successively to 
obtain Tris–HCl-soluble fraction (TS), Triton X-100-soluble fraction 
(TX), and Sarkosyl-soluble fraction (Sar), leaving the pellet fraction 
(ppt). Detection was done with pS396
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Discussion
In our seed-dependent intracellular aggregation model 
of full-length tau using full-length tau fibril seeds [42], 
recombinant tau fibrils were introduced into cells only 
in the presence of a transfection reagent such as Lipo-
fectamine, as was subsequently confirmed by other groups 
[14, 61]. On the other hand, Holmes et al. [18] recently 
reported that heparan sulfate proteoglycans mediate inter-
nalization of tau fibrils and promote tau aggregation. How-
ever, the mechanism by which aggregated extracellular tau 
binds to and enters cells to trigger intracellular tau accumu-
lation is still unknown. In the present study, we show that 
overexpressed APP on the cell surface associates with tau 
fibrils and accelerates intracellular tau aggregation, and that 
both recombinant tau fibrils and pathological tau-enriched 
Sarkosyl-insoluble fraction from AD brains can induce 
intracellular tau aggregation in association with APP. Fur-
thermore, the extracellular domain of APP is required for 
the acceleration of seed-dependent tau aggregation.
APP is predominantly cleaved by α-secretase, generat-
ing soluble APPα and the corresponding C-terminal frag-
ments (CTF-α) [58]. Intact APP can be internalized from 
the cell surface by endocytosis, then β- or γ-secretase 
cleavage can occur intracellularly [25]. The transient 
expression of APP may increase the activity of cellular 
endocytosis and metabolism of APP. It is also known that 
APP has a heparin-binding site in its extracellular region, 
which is thought to be rich in positively charged amino 
acids. Recombinant tau fibrils prepared in the presence 
of heparin or phosphorylated tau aggregates in AD brain 
might associate electrostatically with the heparin-binding 
site of APP and be internalized into cells together with APP 
by endocytosis. Alternatively, the expression of APP may 
influence cell membrane fluidity, because APP is reported 
to bind cholesterol [56] and control its turnover [46], so it 
is possible that aggregated tau may be able to pass through 
cell membrane with altered fluidity to reach the cytoplasm, 
where it functions as seeds for intracellular tau aggregation. 
In any case, extracellular tau fibrils derived from tangle-
bearing cells after cell death or released via some cellular 
secretion system [52, 54] may be incorporated into cells 
expressing APP, triggering intracellular seed-dependent tau 
aggregation and subsequent propagation of tau pathology.
Treatment of cells with Aβ42 did not accelerate intra-
cellular tau aggregation in our cellular model. Given that 
the seed-dependent tau aggregation did not occur in cells 
expressing mutant APP lacking an extracellular domain, 
we consider that APP itself rather than Aβ is required for 
induction of intracellular aggregate formation of tau. Many 
researchers have proposed a link between extracellular Aβ 
deposition and intracellular aggregation of tau, and indeed, 
it has been confirmed that Aβ is associated with tau 
pathology [3, 7, 22, 33]. However, it is still unclear which 
protein pathology appears first, and how the two molecules 
interact with each other. Our present results indicate that 
APP, but not Aβ, binds tau fibrils or pathological tau and 
accelerates incorporation of tau and seed-dependent intra-
cellular accumulation of tau. Since we could not detect any 
significant effect of APP mutations found in rare familial 
forms of AD on tau aggregation in this study, the patho-
logical relevance of these mutations is unclear. However, 
it has been shown that development of AD pathology is 
associated with a 1.5-fold or more increase of expression 
of APP in Down’s syndrome patients [51, 60] and a two-
fold increase in patients with APP gene duplication [15, 
26, 36, 49, 50, 55]. It is not yet clear whether or not there 
is any increase in the expression levels of APP in brains 
of patients with sporadic AD, but it has been reported that 
the APP expression is increased in brains of post-traumatic 
injury patients [13, 47, 48] and animal models [21, 30, 
43, 45, 59]. It is possible that an increase in the APP fol-
lowing injury or damage to the brain may accelerate tau 
accumulation and spreading. Further studies are needed to 
explore the relationship between increase of APP and tau 
pathologies.
Based on the results obtained in this study, we pro-
pose that APP may work as a receptor for uptake of tau 
aggregates into cells and thereby promote seed-dependent 
intracellular tau aggregation. Further studies on the role 
of APP in the pathogenesis of AD and other neurodegen-
erative diseases using our new cellular model for intracel-
lular tau accumulation in cells expressing APP may lead to 
the development of new therapies and pharmaceuticals for 
these diseases.
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